-
1Academic Journal
Πηγή: Scientific and practical specialized journal "Rheumatology of Kazakhstan". :74-80
Θεματικοί όροι: rheumatoid arthritis, autoantibodies, ревматология, серонегативный ревматоидный артрит, ревматоидный артрит, rheumatology, diagnostics, диагностика, seronegative rheumatoid arthritis, аутоантитела, 3. Good health
-
2Academic Journal
Συγγραφείς: D. A. Dibrov, A. S. Avdeeva, M. E. Diatroptov, E. L. Nasonov, Д. А. Дибров, А. С. Авдеева, М. Е. Диатроптов, Е. Л. Насонов
Συνεισφορές: Работа выполнена за счет средств бюджетного финансирования на выполнение государственного задания по теме «Изучение иммунопатологии, диагностики и терапии на ранних стадиях системных ревматических заболеваний» (номер государственного задания № 1021051402790-6).
Πηγή: Rheumatology Science and Practice; Vol 61, No 6 (2023); 751-757 ; Научно-практическая ревматология; Vol 61, No 6 (2023); 751-757 ; 1995-4492 ; 1995-4484
Θεματικοί όροι: серонегативный ревматоидный артрит, anti-CarP, rheumatoid arthritis, ACCP-negative rheumatoid arthritis, seronegative rheumatoid arthritis, анти-Карб, ревматоидный артрит, АЦЦП-негативный ревматоидный артрит
Περιγραφή αρχείου: application/pdf
Relation: https://rsp.mediar-press.net/rsp/article/view/3480/2340; Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001. doi:10.1038/nrdp.2018.1; Дибров ДА. Новые лабораторные биомаркеры ревматоидного артрита. Научно-практическая ревматология. 2021;59(2):201-207. doi:10.47360/1995-4484-2021-201-207; Shi J, van Veelen PA, Mahler M, Janssen GM, Drijfhout JW, Huizinga TW, et al. Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies. Autoimmun Rev. 2014;13(3):225-230. doi:10.1016/j.autrev.2013.10.008; Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, Hörkkö S, Barnard J, et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med. 2007;13(10):1176-1184. doi:10.1038/nm1637; Mydel P, Wang Z, Brisslert M, Hellvard A, Dahlberg LE, Hazen SL, et al. Carbamylation-dependent activation of T cells: A novel mechanism in the pathogenesis of autoimmune arthritis. J Immunol. 2010;184(12):6882-6890. doi:10.4049/jimmunol.1000075; O’Neil LJ, Oliveira CB, Wang X, Navarrete M, Barrera-Vargas A, Merayo-Chalico J, et al. Neutrophil extracellular trap-associated carbamylation and histones trigger osteoclast formation in rheumatoid arthritis. Ann Rheum Dis. 2023;82(5):630-638. doi:10.1136/ard-2022-223568; Li X, Wang Z, Yi H, Xie J, Zhu N. Diagnostic accuracy of anticarbamylated protein antibodies in rheumatoid arthritis: A systematic review and meta-analysis. Clin Lab. 2019;65(12). doi:10.7754/Clin.Lab.2019.190419; Кузнецова ПА, Маслянский АЛ, Лапин СВ, Мазинг АВ, Бэнг Х, Мазуров ВИ. Антитела к различным посттрансляционным модификациям виментина у больных ревматоидным артритом. Современная ревматология. 2017;11(3):44-49. doi: 10/14412/1996-7012-2017-3-44-49; Brink M, Verheul MK, Rönnelid J, Berglin E, Holmdahl R, Toes RE, et al. Anti-carbamylated protein antibodies in the presymptomatic phase of rheumatoid arthritis, their relationship with multiple anti-citrulline peptide antibodies and association with radiological damage. Arthritis Res Ther. 2015;17(1):25. doi:10.1186/s13075-015-0536-2; Jiang X, Trouw LA, van Wesemael TJ, Shi J, Bengtsson C, Källberg H, et al. Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies. Ann Rheum Dis. 2014;73(10):1761-1768. doi:10.1136/annrheumdis-2013-205109; Ajeganova S, van Steenbergen HW, Verheul MK, Forslind K, Hafström I, Toes RE, et al. The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: A study exploring replication and the added value to ACPA and rheumatoid factor. Ann Rheum Dis. 2017;76(1):112-118. doi:10.1136/annrheumdis-2015-208870; Truchetet ME, Dublanc S, Barnetche T, Vittecoq O, Mariette X, Richez C, et al.; Fédération Hospitalo-Universitaire ACRONIM. Association of the presence of anti-carbamylated protein antibodies in early arthritis with a poorer clinical and radiologic outcome: Data from the French ESPOIR cohort. Arthritis Rheumatol. 2017;69(12):2292-2302. doi:10.1002/art.40237; Kolarz B, Ciesla M, Rosenthal AK, Dryglewska M, Majdan M. The value of anti-CarP and anti-PAD4 as markers of rheumatoid arthritis in ACPA/RF negative rheumatoid arthritis patients. Ther Adv Musculoskelet Dis. 2021;13:1759720X21989868. doi:10.1177/1759720X21989868; Shi J, van de Stadt LA, Levarht EW, Huizinga TW, Hamann D, van Schaardenburg D, et al. Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann Rheum Dis. 2014;73(4):780-783. doi:10.1136/annrheumdis-2013-204154; Verheul MK, Böhringer S, van Delft MAM, Jones JD, Rigby WFC, Gan RW, et al. Triple positivity for anti-citrullinated protein autoantibodies, rheumatoid factor, and anti-carbamylated protein antibodies conferring high specificity for rheumatoid arthritis: Implications for Very Early Identification of at-risk individuals. Arthritis Rheumatol. 2018;70(11):1721-1731. doi:10.1002/art.40562; Sidiras P, Spruyt D, Gangji V, Imbault V, Sokolova T, Durez P, et al. Antibodies against carbamylated proteins: Prevalence and associated disease characteristics in Belgian patients with rheumatoid arthritis or other rheumatic diseases. Scand J Rheumatol. 2021;50(2): 118-123. doi:10.1080/03009742.2020.1798500; Zhang B, Lei Y, Li X, Gao Z, Xia L, Lu J, et al. Elevated levels of anti-carbamylated protein antibody in patients with rheumatoid arthritis: association with disease activity and bone destruction. J Investig Med. 2020;68(6):1186-1192. doi:10.1136/jim-2019-001249; Elsayed SA, Esmail MA, Ali RM, Mohafez OM. Diagnostic and prognostic value of anti-CarP antibodies in a sample of Egyptian rheumatoid arthritis patients. Clin Rheumatol. 2019;38(10):2683-2689. doi:10.1007/s10067-019-04616-z; Zhu H, Zhao LJ, Zhou Y, Chen Y. [Significance of anti-carbamylated protein antibodies in patients with rheumatoid arthritis-associated intersitial lung disease]. Beijing Da Xue Xue Bao Yi Xue Ban. 2019;51(6):1003-1007 (In Chinese). doi:10.19723/j.issn.1671-167X.2019.06.004; Castellanos-Moreira R, Rodríguez-García SC, Gomara MJ, Ruiz-Esquide V, Cuervo A, Casafont-Solé I, et al. Anti-carbamylated proteins antibody repertoire in rheumatoid arthritis: Evidence of a new autoantibody linked to interstitial lung disease. Ann Rheum Dis. 2020;79(5):587-594. doi:10.1136/annrheumdis-2019-216709; Vidal-Bralo L, Perez-Pampin E, Regueiro C, Montes A, Varela R, Boveda MD. Anti-carbamylated protein autoantibodies associated with mortality in Spanish rheumatoid arthritis patients. PLoS One. 2017;12(7):e0180144. doi:10.1371/journal.pone.0180144; Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44-48. doi:10.1002/art.1780380107; Ziegelasch M, van Delft MA, Wallin P, Skogh T, Magro-Checa C, Steup-Beekman GM, et al. Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: Results from two well-defined European cohorts. Arthritis Res Ther. 2016;18(1):289. doi:10.1186/s13075-016-1192-x; Nakabo S, Yoshifuji H, Hashimoto M, Imura Y, Nakashima R, Murakami K, et al. Anti-carbamylated protein antibodies are detectable in various connective tissue diseases. J Rheumatol. 2017;44(9):1384-1388. doi:10.3899/jrheum.161432; Pecani A, Alessandri C, Spinelli FR, Priori R, Riccieri V, Di Franco M, et al. Prevalence, sensitivity and specificity of antibodies against carbamylated proteins in a monocentric cohort of patients with rheumatoid arthritis and other autoimmune rheumatic diseases. Arthritis Res Ther. 2016;18(1):276. doi:10.1186/s13075-016-1173-0; Bergum B, Koro C, Delaleu N, Solheim M, Hellvard A, Binder V, et al. Antibodies against carbamylated proteins are present in primary Sjögren’s syndrome and are associated with disease severity. Ann Rheum Dis. 2016;75(8):1494-1500. doi:10.1136/annrheum-dis-2015-207751; Насонов ЕЛ, Авдеева АС, Дибров ДА. Ревматоидный артрит как клинико-иммунологический синдром: фокус на серонегативный субтип заболевания. Научно-практическая ревматология. 2023;61(3):276-291 doi:10.47360/1995-4484-2023-276-291; Reed E, Hedström AK, Hansson M, Mathsson-Alm L, Brynedal B, Saevarsdottir S, et al. Presence of autoantibodies in “seronegative” rheumatoid arthritis associates with classical risk factors and high disease activity. Arthritis Res Ther. 2020;22(1):170. doi:10.1186/s13075-020-02191-2
-
3Academic Journal
Συγγραφείς: D. A. Dibrov, A. S. Avdeeva, V. V. Rybakova, N. V. Demidova, E. L. Nasonov, Д. А. Дибров, А. С. Авдеева, В. В. Рыбакова, Н. В. Демидова, Е. Л. Насонов
Πηγή: Rheumatology Science and Practice; Vol 61, No 2 (2023); 207-213 ; Научно-практическая ревматология; Vol 61, No 2 (2023); 207-213 ; 1995-4492 ; 1995-4484
Θεματικοί όροι: клинические особенности, rheumatoid arthritis, ACPA-negative rheumatoid arthritis, seronegative rheumatoid arthritis, clinical features, ревматоидный артрит, АЦЦП-негативный ревматоидный артрит, серонегативный ревматоидный артрит
Περιγραφή αρχείου: application/pdf
Relation: https://rsp.mediar-press.net/rsp/article/view/3323/2276; Насонов ЕЛ (ред.). Российские клинические рекомендации. Ревматология. М.:ГЭОТАР-Медиа;2020.; Burgers LE, van Steenbergen HW, Ten Brinck RM, Huizinga TW, van der Helm-van Mil AH. Differences in the symptomatic phase preceding ACPA-positive and ACPA-negative RA: A longitudinal study in arthralgia during progression to clinical arthritis. Ann Rheum Dis. 2017;76(10):1751-1754. doi:10.1136/annrheumdis-2017-211325; Pertsinidou E, Manivel VA, Westerlind H, Klareskog L, Alfredsson L, Mathsson-Alm L, et al. Rheumatoid arthritis autoantibodies and their association with age and sex. Clin Exp Rheumatol. 2021;39(4):879-882.; Boeters DM, Mangnus L, Ajeganova S, Lindqvist E, Svensson B, Toes REM, et al. The prevalence of ACPA is lower in rheumatoid arthritis patients with an older age of onset but the composition of the ACPA response appears identical. Arthritis Res Ther. 2017;19(1):115. doi:10.1186/s13075-017-1324-y; Arnold MB, Bykerk VP, Boire G, Haraoui BP, Hitchon C, Thorne C, et al.; CATCH Investigators. Are there differences between young- and older-onset early inflammatory arthritis and do these impact outcomes? An analysis from the CATCH cohort. Rheumatology (Oxford). 2014;53(6):1075-1086. doi:10.1093/rheumatology/ket449; Nilsson J, Andersson MLE, Hafström I, Svensson B, Forslind K, Ajeganova S, et al. Influence of age and sex on disease course and treatment in rheumatoid arthritis. Open Access Rheumatol. 2021;13:123-138. doi:10.2147/OARRR.S306378; van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther. 2005;7(5):949-958. doi:10.1186/ar1767; Ursum J, Bos WH, van Dillen N, Dijkmans BA, van Schaardenburg D. Levels of anti-citrullinated protein antibodies and IgM rheumatoid factor are not associated with outcome in early arthritis patients: A cohort study. Arthritis Res Ther. 2010;12(1):8. doi:10.1186/ar2907; Bergstra SA, Couto MC, Govind N, Chopra A, Salomon Escoto K, Murphy E, et al. Impact of the combined presence of erosions and ACPA on rheumatoid arthritis disease activity over time: Results from the METEOR registry. RMD Open. 2019;5(2):e000969. doi:10.1136/rmdopen-2019-000969; van den Broek M, Dirven L, Klarenbeek NB, Molenaar TH, Han KH, Kerstens PJ, et al. The association of treatment response and joint damage with ACPA-status in recent-onset RA: A subanalysis of the 8-year follow-up of the BeSt study. Ann Rheum Dis. 2012;71(2):245-248. doi:10.1136/annrheumdis-2011-200379; Seegobin SD, Ma MH, Dahanayake C, Cope AP, Scott DL, Lewis CM, et al. ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: Secondary analysis of a randomized controlled trial. Arthritis Res Ther. 2014;16(1):13. doi:10.1186/ar4439; Shpatz R, Braun-Moscovici Y, Balbir-Gurman A. ACPA antibodies titer at the time of rheumatoid arthritis diagnosis is not associated with disease severity. Isr Med Assoc J. 2021;23(10):646-650.; Boer AC, Boonen A, van der Helm-van Mil AHM. Is anticitrullinated protein antibody-positive rheumatoid arthritis still a more severe disease than anti-citrullinated protein antibody-negative rheumatoid arthritis? A longitudinal cohort study in rheumatoid arthritis patients diagnosed from 2000 onward. Arthritis Care Res (Hoboken). 2018;70(7):987-996. doi:10.1002/acr.23497; Farragher TM, Lunt M, Plant D, Bunn DK, Barton A, Symmons DP. Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies. Arthritis Care Res (Hoboken). 2010;62(5):664-675. doi:10.1002/acr.20207; Mouterde G, Rincheval N, Lukas C, Daien C, Saraux A, Dieudé P, et al. Outcome of patients with early arthritis without rheumatoid factor and ACPA and predictors of rheumatoid arthritis in the ESPOIR cohort. Arthritis Res Ther. 2019;21(1):140. doi:10.1186/s13075-019-1909-8; Katchamart W, Koolvisoot A, Aromdee E, Chiowchanwesa wakit P, Muengchan C. Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment out-comes in patients with rheumatoid arthritis. Rheumatol Int. 2015;35(10):1693-1699. doi:10.1007/s00296-015-3271-8; del Val del Amo N, Ibanez Bosch R, Fito Manteca C, Gutierrez Polo R, Loza Cortina E. Anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: relation with disease aggressiveness. Clin Exp Rheumatol. 2006;24(3):281-286.; Barra L, Pope JE, Orav JE, Boire G, Haraoui B, Hitchon C, et al.; CATCH Investigators. Prognosis of seronegative patients in a large prospective cohort of patients with early inflammatory arthritis. J Rheumatol. 2014;41(12):2361-2369. doi:10.3899/jrheum.140082; Nordberg LB, Lillegraven S, Lie E, Aga AB, Olsen IC, Hammer HB, et al.; ARCTIC working group. Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-naïve patients classified according to the 2010 ACR/EULAR criteria. Ann Rheum Dis. 2017;76(2):341-345. doi:10.1136/annrheumdis-2015-208873; Choi S, Lee KH. Clinical management of seronegative and seropositive rheumatoid arthritis: A comparative study. PLoS One. 2018;13(4):e0195550. doi:10.1371/journal.pone.0195550; Jonsson MK, Hensvold AH, Hansson M, Aga AB, Sexton J, Mathsson-Alm L, et al. The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy. Arthritis Res Ther. 2018;20(1):146. doi:10.1186/s13075-018-1635-7.; Zhao SS, Nikiphorou E, Young A, Kiely PDW. Large joints are progressively involved in rheumatoid arthritis irrespective of rheumatoid factor status-results from the early rheumatoid arthritis study. Rheumatol Int. 2022;42(4):621-629. doi:10.1007/s00296-021-04931-2.; Gadeholt O, Hausotter K, Eberle H, Klink T, Pfeil A. Differing X-ray patterns in seronegative and seropositive rheumatoid arthritis. Clin Rheumatol. 2019;38(9):2403-2410. doi:10.1007/s10067-019-04602-5.; Grosse J, Allado E, Roux C, Pierreisnard A, Couderc M, Clerc-Urmes I, et al. ACPA-positive versus ACPA-negative rheumatoid arthritis: Two distinct erosive disease entities on radiography and ultrasonography. Rheumatol Int. 2020;40(4):615-624. doi:10.1007/s00296-019-04492-5; Joo YB, Park YJ, Park KS, Kim KJ. Association of cumulative anti-cyclic citrullinated protein antibodies with radiographic progression in patients with rheumatoid arthritis. Clin Rheumatol. 2019;38(9):2423-2432. doi:10.1007/s10067-019-04554-w; Forslind K, Ahlmén M, Eberhardt K, Hafström I, Svensson B; BARFOT Study Group. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: Role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis. 2004;63(9):1090-1095. doi:10.1136/ard.2003.014233; Mustila A, Korpela M, Haapala AM, Kautiainen H, Laasonen L, Möttönen T, et al. Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease-modifying antirheumatic drug strategies. Clin Exp Rheumatol. 2011;29(3):500-505.; Coffey CM, Crowson CS, Myasoedova E, Matteson EL, Davis JM 3rd. Evidence of diagnostic and treatment delay in seronegative rheumatoid arthritis: Missing the window of opportunity. Mayo Clin Proc. 2019;94(11):2241-2248. doi:10.1016/j.mayocp.2019.05.023; Paalanen K, Puolakka K, Nikiphorou E, Hannonen P, Sokka T. Is seronegative rheumatoid arthritis true rheumatoid arthritis? A nationwide cohort study. Rheumatology (Oxford). 2021;14;60(5):2391-2395. doi:10.1093/rheumatology/keaa623; Paalanen K, Rannio K, Rannio T, Asikainen J, Hannonen P, Sokka T. Does early seronegative arthritis develop into rheumatoid arthritis? A 10-year observational study. Clin Exp Rheumatol. 2019;37(1):37-43.
-
4Academic Journal
Συγγραφείς: E. L. Nasonov, A. S. Avdeeva, D. A. Dibrov, Е. Л. Насонов, А. С. Авдеева, Д. А. Дибров
Πηγή: Rheumatology Science and Practice; Vol 61, No 3 (2023); 276-291 ; Научно-практическая ревматология; Vol 61, No 3 (2023); 276-291 ; 1995-4492 ; 1995-4484
Θεματικοί όροι: новые аутоантитела при ревматоидном артрите, seronegative rheumatoid arthritis, rheumatoid factor, anti-citrullinated protein antibodies, new autoantibodies in rheumatoid arthritis, серопозитивный ревматоидный артрит, серонегативный ревматоидный артрит, ревматоидный фактор, антитела к цитруллинированным белкам
Περιγραφή αρχείου: application/pdf
Relation: https://rsp.mediar-press.net/rsp/article/view/3355/2283; Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, Kavanaugh A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001. doi:10.1038/nrdp.2018.1; McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205-2219. doi:10.1056/NEJMra1004965; Gravallese EM, Firestein GS. Rheumatoid arthritis – Common origins, divergent mechanisms. N Engl J Med. 2023;388(6):529-542. doi:10.1056/NEJMra2103726; Насонов ЕЛ. Проблемы иммунопатологии ревматоидного артрита: эволюция болезни. Научно-практическая ревматология. 2017;55(3):277-294. doi:10.14412/1995-4484-2017-277-294; Насонов ЕЛ. Фармакотерапия ревматоидного артрита: новая стратегия, новые мишени. Научно-практическая ревматология. 2017;55(4):409-419. doi:10.14412/1995-4484-2017-409-419; Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175-187. doi:10.1136/annrheumdis-2017-211555; McGonagle D, Watad A, Savic S. Mechanistic immunological based classification of rheumatoid arthritis. Autoimmun Rev. 2018;17(11):1115-1123. doi:10.1016/j.autrev.2018.06.001; Sokolova MV, Schett G, Steffen U. Autoantibodies in rheumatoid arthritis: Historical background and novel findings. Clin Rev Allergy Immunol. 2022;63(2):138-151. doi:10.1007/s12016-021-08890-1; Volkov M, van Schie KA, van der Woude D. Autoantibodies and B cells: The ABC of rheumatoid arthritis pathophysiology. Immunol Rev. 2020;294(1):148-163. doi:10.1111/imr.12829; Pouw JN, Leijten EFA, van Laar JM, Boes M. Revisiting B cell tolerance and autoantibodies in seropositive and seronegative autoimmune rheumatic disease (AIRD). Clin Exp Immunol. 2021;203(2):160-173. doi:10.1111/cei.13542; Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-2581. doi:10.1002/art.27584; Wu CY, Yang HY, Lai JH. Anti-citrullinated protein antibodies in patients with rheumatoid arthritis: Biological effects and mechanisms of immunopathogenesis. Int J Mol Sci. 2020;21(11):4015. doi:10.3390/ijms21114015; Catrina A, Krishnamurthy A, Rethi B. Current view on the pathogenic role of anti-citrullinated protein antibodies in rheumatoid arthritis. RMD Open. 2021;7(1):e001228. doi:10.1136/rmdopen-2020-001228; Scherer HU, van der Woude D, Toes REM. From risk to chronicity: Evolution of autoreactive B cell and antibody responses in rheumatoid arthritis. Nat Rev Rheumatol. 2022;18(7):371-383. doi:10.1038/s41584-022-00786-4; Lenti MV, Rossi CM, Melazzini F, Gastaldi M, Bugatti S, Rotondi M, et al. Seronegative autoimmune diseases: A challenging diagnosis. Autoimmun Rev. 2022;21(9):103143. doi:10.1016/j.autrev.2022.103143; Moll JM. Seronegative arthropathies. J R Soc Med. 1983;76(6):445-448. doi:10.1177/014107688307600601; Boeters DM, Gaujoux-Viala C, Constantin A, van der Helmvan Mil AHM. The 2010 ACR/EULAR criteria are not sufficiently accurate in the early identification of autoantibody-negative rheumatoid arthritis: Results from the Leiden-EAC and ESPOIR cohorts. Semin Arthritis Rheum. 2017;47(2):170-174. doi:10.1016/j.semarthrit.2017.04.009; Paalanen K, Puolakka K, Nikiphorou E, Hannonen P, Sokka T. Is seronegative rheumatoid arthritis true rheumatoid arthritis? A nationwide cohort study. Rheumatology (Oxford). 2021;60(5):2391-2395. doi:10.1093/rheumatology/keaa623; Mease PJ, Bhutani MK, Hass S, Yi E, Hur P, Kim N. Comparison of clinical manifestations in rheumatoid arthritis vs. spondyloarthritis: A systematic literature review. Rheumatol Ther. 2022; 9(2):331-378. doi:10.1007/s40744-021-00407-8; Paalanen K, Rannio K, Rannio T, Asikainen J, Hannonen P, Sokka T. Does early seronegative arthritis develop into rheumatoid arthritis? A 10-year observational study. Clin Exp Rheumatol. 2019; 37(1):37-43.; Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al.; T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631-637. doi:10.1136/ard.2009.123919; Matthijssen XME, Niemantsverdriet E, Huizinga TWJ, van der Helm-van Mil AHM. Enhanced treatment strategies and distinct disease outcomes among autoantibody-positive and -negative rheumatoid arthritis patients over 25 years: A longitudinal cohort study in the Netherlands. PLoS Med. 2020;17(9):e1003296. doi:10.1371/journal.pmed.1003296; McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389(10086):2328-2337. doi:10.1016/S0140-6736(17)31472-1; Malmström V, Catrina AI, Klareskog L. The immunopathogenesis of seropositive rheumatoid arthritis: From triggering to targeting. Nat Rev Immunol. 2017;17(1):60-75. doi:10.1038/nri.2016.124; Roodenrijs NMT, Welsing PMJ, van Roon J, Schoneveld JLM, van der Goes MC, Nagy G, et al. Mechanisms underlying DMARD inefficacy in difficult-to-treat rheumatoid arthritis: A narrative review with systematic literature search. Rheumatology (Oxford). 2022;61(9):3552-3566. doi:10.1093/rheumatology/keac114; De Stefano L, D’Onofrio B, Manzo A, Montecucco C, Bugatti S. The genetic, environmental, and immunopathological complexity of autoantibody-negative rheumatoid arthritis. Int J Mol Sci. 2021;22(22):12386. doi:10.3390/ijms222212386; Li K, Wang M, Zhao L, Liu Y, Zhang X. ACPA-negative rheumatoid arthritis: From immune mechanisms to clinical translation. EBioMedicine. 2022;83:104233. doi:10.1016/j.ebiom.2022.104233; Дибров ДА. АЦЦП-негативный ревматоидный артрит – клинические и иммунологические особенности. Научно-практическая ревматология. 2022;60(3):314-326. doi:10.47360/1995-4484-2022-314-326; Padyukov L. Genetics of rheumatoid arthritis. Semin Immunopathol. 2022;44(1):47-62. doi:10.1007/s00281-022-00912-0; Frisell T, Holmqvist M, Källberg H, Klareskog L, Alfredsson L, Askling J. Familial risks and heritability of rheumatoid arthritis: Role of rheumatoid factor/anti-citrullinated protein antibody status, number and type of affected relatives, sex, and age. Arthritis Rheum. 2013;65(11):2773-2782. doi:10.1002/art.38097; Frisell T, Hellgren K, Alfredsson L, Raychaudhuri S, Klareskog L, Askling J. Familial aggregation of arthritis-related diseases in seropositive and seronegative rheumatoid arthritis: A register-based case-control study in Sweden. Ann Rheum Dis. 2016;75(1):183-189. doi:10.1136/annrheumdis-2014-206133; Kirino Y, Remmers EF. Genetic architectures of seropositive and seronegative rheumatic diseases. Nat Rev Rheumatol. 2015;11(7):401-414. doi:10.1038/nrrheum.2015.41; Padyukov L, Seielstad M, Ong RT, Ding B, Rönnelid J, Seddighzadeh M, et al.; Epidemiological Investigation of Rheumatoid Arthritis (EIRA) study group. A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPAnegative rheumatoid arthritis. Ann Rheum Dis. 2011;70(2):259-265. doi:10.1136/ard.2009.126821; Regueiro C, Casares-Marfil D, Lundberg K, Knevel R, AcostaHerrera M, Rodriguez-Rodriguez L, et al. HLA-B*08 identified as the most prominently associated major histocompatibility complex locus for anti-carbamylated protein antibody-positive/anticyclic citrullinated peptide-negative rheumatoid arthritis. Arthritis Rheumatol. 2021;73(6):963-969. doi:10.1002/art.41630; Saevarsdottir S, Stefansdottir L, Sulem P, Thorleifsson G, Ferkingstad E, Rutsdottir G, et al.; Members of the DBDS Genomic Consortium; Danish RA Genetics Working Group; Swedish Rheumatology Quality Register Biobank Study Group (SRQb). Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset. Ann Rheum Dis. 2022;81(8):1085-1095. doi:10.1136/annrheumdis-2021-221754; Ishigaki K, Sakaue S, Terao C, Luo Y, Sonehara K, Yamaguchi K, et al. Trans-ancestry genome-wide association study identifies novel genetic mechanisms in rheumatoid arthritis. medRxiv. 2021;2021.12.01.21267132. doi:10.1101/2021.12.01.21267132; Wei WH, Viatte S, Merriman TR, Barton A, Worthington J. Genotypic variability based association identifies novel non-additive loci DHCR7 and IRF4 in sero-negative rheumatoid arthritis. Sci Rep. 2017;7(1):5261. doi:10.1038/s41598-017-05447-1; Yuan S, Li X, Lin A, Larsson SC. Interleukins and rheumatoid arthritis: Bi-directional Mendelian randomization investigation. Semin Arthritis Rheum. 2022;53:151958. doi:10.1016/j.semarthrit.2022.151958; Chang C, Xu L, Zhang R, Jin Y, Jiang P, Wei K, et al. MicroRNA-mediated epigenetic regulation of rheumatoid arthritis susceptibility and pathogenesis. Front Immunol. 2022;13:838884. doi:10.3389/fimmu.2022.838884; Jasemi S, Erre GL, Cadoni ML, Bo M, Sechi LA. Humoral response to microbial biomarkers in rheumatoid arthritis patients. J Clin Med. 2021;10(21):5153. doi:10.3390/jcm10215153; Kronzer VL, Westerlind H, Alfredsson L, Crowson CS, Klareskog L, Holmqvist M, et al. Allergic conditions and risk of rheumatoid arthritis: A Swedish case-control study. RMD Open. 2022;8(1):e002018. doi:10.1136/rmdopen-2021-002018; Morotti A, Sollaku I, Franceschini F, Cavazzana I, Fredi M, Sala E, et al. Systematic review and meta-analysis on the association of occupational exposure to free crystalline silica and rheumatoid arthritis. Clin Rev Allergy Immunol. 2022;62(2):333-345. doi:10.1007/s12016-021-08846-5; Curtis JR, Jain A, Askling J, Bridges SL Jr, Carmona L, Dixon W, et al. A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum. 2010;40(1):2-1r4.e1. doi:10.1016/j.semarthrit.2010.03.003; Courvoisier DS, Chatzidionysiou K, Mongin D, Lauper K, Mariette X, Morel J, et al. The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: Results from a collaboration of 16 registries. Rheumatology (Oxford). 2021;60(2):820-828. doi:10.1093/rheumatology/keaa393; Brinkmann GH, Norvang V, Norli ES, Grøvle L, Haugen AJ, Lexberg ÅS, et al. Treat to target strategy in early rheumatoid arthritis versus routine care – A comparative clinical practice study. Semin Arthritis Rheum. 2019;48(5):808-814. doi:10.1016/j.semarthrit.2018.07.004; Balduzzi S, Scirè CA, Sakellariou G, Benaglio F, Bugatti S, Montecucco C, et al. In early inflammatory polyarthritis more intensive management according to the 2010 ACR/EULAR criteria leads to higher rates of clinical remission: Comparison of two cohorts treated according to different treat-to-target protocols. Clin Exp Rheumatol. 2017;35(3):401-405.; Elfving P, Kononoff A, Huhtakangas J, Kautiainen H, Savolainen E, Arstila L, et al. Incidence of seropositive rheumatoid arthritis in population-based studies in Northern Savo, Finland, during 1980–2020. Rheumatol Int. 2023;43(4):659-666. doi:10.1007/s00296-022-05268-0; Enzer I, Dunn G, Jacobsson L, Bennett PH, Knowler WC, Silman A. An epidemiologic study of trends in prevalence of rheumatoid factor seropositivity in Pima Indians: evidence of a decline due to both secular and birth-cohort influences. Arthritis Rheum. 2002;46(7):1729-1734. doi:10.1002/art.10360; Myasoedova E, Davis J, Matteson EL, Crowson CS. Is the epidemiology of rheumatoid arthritis changing? Results from a population-based incidence study, 1985–2014. Ann Rheum Dis. 2020;79(4):440-444. doi:10.1136/annrheumdis-2019-216694; Hadwen B, Yu R, Cairns E, Barra L. Presence of autoantibodies in males and females with rheumatoid arthritis: A systematiceview and metaanalysis. J Rheumatol. 2022;49(7):663-671. doi:10.3899/jrheum.211020; Matthjssen XME, Huizinga TWJ, van der Helm, van Mil AHM. Increasing incidence of autoantibody-negative RA is replicated and is partly explained by an aging population. Ann Rheum Dis. 2022;81:e69. doi:10.1136/annrheumdis-2020-217609; Takanashi S, Takeuchi T, Kaneko Y. Effects of aging on rheumatoid factor and anticyclic citrullinated peptide antibody positivity in patients with rheumatoid arthritis. J Rheumatol. 2023;50(3):330-334. doi:10.3899/jrheum.220526; Boeters DM, Mangnus L, Ajeganova S, Lindqvist E, Svensson B, Toes REM, et al. The prevalence of ACPA is lower in rheumatoid arthritis patients with an older age of onset but the composition of the ACPA response appears identical. Arthritis Res Ther. 2017;19(1):115. doi:10.1186/s13075-017-1324-y; Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-324. doi:10.1002/art.1780310302; Nordberg LB, Lillegraven S, Lie E, Aga AB, Olsen IC, Hammer HB, et al.; ARCTIC working group. Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-naïve patients classified according to the 2010 ACR/EULAR criteria. Ann Rheum Dis. 2017;76(2):341-345. doi:10.1136/annrheumdis-2015-208873; Van Hoovels L, Studenic P, Sieghart D, Steiner G, Bossuyt X, Rönnelid J. Impact of autoimmune serology test results on RA classification and diagnosis. J Transl Autoimmun. 2022;5:100142. doi:10.1016/j.jtauto.2022.100142; Hua C, Daien CI, Combe B, Landewe R. Diagnosis, prognosis and classification of early arthritis: Results of a systematic review informing the 2016 update of the EULAR recommendations for the management of early arthritis. RMD Open. 2017;3(1):e000406. doi:10.1136/rmdopen-2016-000406; Norli ES, Brinkmann GH, Kvien TK, Bjørneboe O, Haugen AJ, Nygaard H, et al. Self-limiting arthritis among patients fulfilling the 2010 ACR/EULAR classification criteria for rheumatoid arthritis in a very early arthritis cohort. Semin Arthritis Rheum. 2016;46(3):272-278. doi:10.1016/j.semarthrit.2016.07.004; Leu Agelii M, Hafström I, Svensson B, Ajeganova S, Forslind K, Andersson M, et al. Misdiagnosis of rheumatoid arthritis in a longterm cohort of early arthritis based on the ACR-1987 classification criteria. Open Access Rheumatol. 2022;14:187-194. doi:10.2147/OARRR.S372724; Combe B, Landewe R, Daien CI, Hua C, Aletaha D, ÁlvaroGracia JM, et al. 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis. 2017;76(6): 948-959. doi:10.1136/annrheumdis-2016-210602; Krekeler M, Baraliakos X, Tsiami S, Braun J. High prevalence of chondrocalcinosis and frequent comorbidity with calcium pyrophosphate deposition disease in patients with seronegative rheumatoid arthritis. RMD Open. 2022;8(2):e002383. doi:10.1136/rmdopen-2022-002383; Paalanen K, Rannio K, Rannio T, Asikainen J, Hannonen P, Sokka T. Prevalence of calcium pyrophosphate deposition disease in a cohort of patients diagnosed with seronegative rheumatoid arthritis. Clin Exp Rheumatol. 2020;38(1):99-106.; Lewis MJ, Barnes MR, Blighe K, Goldmann K, Rana S, Hackney JA, et al. Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes. Cell Rep. 2019;28(9):2455-2470.e5. doi:10.1016/j.celrep.2019.07.091; Humby F, Lewis M, Ramamoorthi N, Hackney JA, Barnes MR, Bombardieri M, et al. Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients. Ann Rheum Dis. 2019;78(6):761-772. doi:10.1136/annrheumdis-2018-214539; Vickovic S, Schapiro D, Carlberg K, Lötstedt B, Larsson L, Hildebrandt F, et al. Three-dimensional spatial transcriptomics uncovers cell type localizations in the human rheumatoid arthritis synovium. Commun Biol. 2022;5(1):129. doi:10.1038/s42003-022-03050-3; Argyriou A, Wadsworth MH 2nd, Lendvai A, Christensen SM, Hensvold AH, Gerstner C, et al. Single cell sequencing identifies clonally expanded synovial CD4+ TPH cells expressing GPR56 in rheumatoid arthritis. Nat Commun. 2022;13(1):4046. doi:10.1038/s41467-022-31519-6; Wu X, Liu Y, Jin S, Wang M, Jiao Y, Yang B, et al. Single-cell sequencing of immune cells from anticitrullinated peptide antibody positive and negative rheumatoid arthritis. Nat Commun. 2021;12(1):4977. doi:10.1038/s41467-021-25246-7; Floudas A, Canavan M, McGarry T, Mullan R, Nagpal S, Veale DJ, et al. ACPA status correlates with differential immune profile in patients with rheumatoid arthritis. Cells. 2021;10(3):647. doi:10.3390/cells10030647; Walker LSK. The link between circulating follicular helper T cells and autoimmunity. Nat Rev Immunol. 2022;22(9):567-575. doi:10.1038/s41577-022-00693-5; Pratt AG, Swan DC, Richardson S, Wilson G, Hilkens CM, Young DA, et al. A CD4 T cell gene signature for early rheumatoid arthritis implicates interleukin 6-mediated STAT3 signalling, particularly in anti-citrullinated peptide antibody-negative disease. Ann Rheum Dis. 2012;71(8):1374-1381. doi:10.1136/annrheumdis-2011-200968; Anderson AE, Pratt AG, Sedhom MA, Doran JP, Routledge C, Hargreaves B, et al. IL-6-driven STAT signalling in circulating CD4+ lymphocytes is a marker for early anticitrullinated peptide antibody-negative rheumatoid arthritis. Ann Rheum Dis. 2016;75(2):466-473. doi:10.1136/annrheumdis-2014-205850; van Oosterhout M, Bajema I, Levarht EW, Toes RE, Huizinga TW, van Laar JM. Differences in synovial tissue infiltrates between anti-cyclic citrullinated peptide-positive rheumatoid arthritis and anti-cyclic citrullinated peptide-negative rheumatoid arthritis. Arthritis Rheum. 2008;58(1):53-60. doi:10.1002/art.23148; Liang Z, Wang N, Shang L, Wang Y, Feng M, Liu G, et al. Evaluation of the immune feature of ACPA-negative rheumatoid arthritis and the clinical value of matrix metalloproteinase-3. Front Immunol. 2022;13:939265. doi:10.3389/fimmu.2022.939265; Mun S, Lee J, Park M, Shin J, Lim MK, Kang HG. Serum biomarker panel for the diagnosis of rheumatoid arthritis. Arthritis Res Ther. 2021;23(1):31. doi:10.1186/s13075-020-02405-7; Yang ML, Sodré FMC, Mamula MJ, Overbergh L. Citrullination and PAD enzyme biology in type 1 diabetes – Regulators of inflammation, autoimmunity, and pathology. Front Immunol. 2021;12: 678953. doi:10.3389/fimmu.2021.678953; Liu X, Zhu L, Liu H, Cai Q, Yun Z, Sun F, et al. Non-criteria antiphospholipid antibodies in antiphospholipid syndrome: Diagnostic value added. Front Immunol. 2022;13:972012. doi:10.3389/fimmu.2022.972012; Truglia S, Mancuso S, Capozzi A, Recalchi S, Riitano G, Longo A, et al. ‘Non-criteria antiphospholipid antibodies’: Bridging the gap between seropositive and seronegative antiphospholipid syndrome. Rheumatology. 2022;61(2):826-833. doi:10.1093/rheumatology/keab414; Gómez-Bañuelos E, Fava A, Andrade F. An update on autoantibodies in systemic lupus erythematosus. Curr Opin Rheumatol. 2023;35(2):61-67. doi:10.1097/BOR.0000000000000922; Martín-Nares E, Hernández-Molina G. Novel autoantibodies in Sjögren’s syndrome: A comprehensive review. Autoimmun Rev. 2019;18(2):192-198. doi:10.1016/j.autrev.2018.09.003; Vílchez-Oya F, Balastegui Martin H, García-Martínez E, Corominas H. Not all autoantibodies are clinically relevant. Classic and novel autoantibodies in Sjögren’s syndrome: A critical review. Front Immunol. 2022;13:1003054. doi:10.3389/fimmu.2022.1003054; Davies EJ, Jones GT, Sengupta R. Autoantibodies in ankylosing spondylitis: A systematic literature review. Rheumatology. 2022;61(Suppl 1): keac133.262. doi:10.1093/rheumatology/keac133.262; Xu S, Zhang X, Chen Y, Ma Y, Deng J, Gao X, et al. Anti-CD74 antibodies in spondyloarthritis: A systematic review and meta-analysis. Semin Arthritis Rheum. 2021;51(1):7-14. doi:10.1016/j.semarthrit.2020.12.002; Ten Bergen LL, Petrovic A, Aarebrot AK, Appel S. Current knowledge on autoantigens and autoantibodies in psoriasis. Scand J Immunol. 2020;92(4):e12945. doi:10.1111/sji.12945; Haro I, Sanmartí R, Gómara MJ. Implications of post-translational modifications in autoimmunity with emphasis on citrullination, homocitrullination and acetylation for the pathogenesis, diagnosis and prognosis of rheumatoid arthritis. Int J Mol Sci. 2022;23(24):15803. doi:10.3390/ijms232415803; Moritz CP, Paul S, Stoevesandt O, Tholance Y, Camdessanché JP, Antoine JC. Autoantigenomics: Holistic characterization of autoantigen repertoires for a better understanding of autoimmune diseases. Autoimmun Rev. 2020;19(2):102450. doi:10.1016/j.autrev.2019.102450; Rönnelid J, Hansson M, Mathsson-Alm L, Cornillet M, Reed E, Jakobsson PJ, et al. Anticitrullinated protein/peptide antibody multiplexing defines an extended group of ACPA-positive rheumatoid arthritis patients with distinct genetic and environmental determinants. Ann Rheum Dis. 2018;77(2):203-211. doi:10.1136/annrheumdis-2017-211782; Sieghart D, Platzer A, Studenic P, Alasti F, Grundhuber M, Swiniarski S, et al. Determination of autoantibody isotypes increases the sensitivity of serodiagnostics in rheumatoid arthritis. Front Immunol. 2018;9:876. doi:10.3389/fimmu.2018.00876; Konig MF, Giles JT, Nigrovic PA, Andrade F. Antibodies to native and citrullinated RA33 (hnRNP A2/B1) challenge citrullination as the inciting principle underlying loss of tolerance in rheumatoid arthritis. Ann Rheum Dis. 2016;75(11):2022-2028. doi:10.1136/annrheumdis-2015-208529; Reed E, Hedström AK, Hansson M, Mathsson-Alm L, Brynedal B, Saevarsdottir S, et al. Presence of autoantibodies in “seronegative” rheumatoid arthritis associates with classical risk factors and high disease activity. Arthritis Res Ther. 2020;22(1):170. doi:10.1186/s13075-020-02191-2; Sidiras P, Lechanteur J, Imbault V, Sokolova T, Durez P, Gangji V, et al. Human carbamylome description identifies carbamylated α2-macroglobulin and hemopexin as two novel autoantigens in early rheumatoid arthritis. Rheumatology (Oxford). 2022;61(7):2826-2834. doi:10.1093/rheumatology/keab838; Moore RE, Wang T, Duvvuri B, Feser ML, Deane KD, Solomon JJ, et al. Prediction of erosive disease development by antimitochondrial antibodies in rheumatoid arthritis. Arthritis Rheumatol. 2023;75(6):890-899. doi:10.1002/art.42428; Lönnblom E, Leu Agelii M, Sareila O, Cheng L, Xu B, Viljanen J, et al. Autoantibodies to disease-related proteins in joints as novel biomarkers for the diagnosis of rheumatoid arthritis. Arthritis Rheumatol. 2023 Jan 31. doi:10.1002/art.42463; Bason C, Barbieri A, Martinelli N, Olivieri B, Argentino G, Bartoloni E, et al. Identification of a novel serological marker in seronegative rheumatoid arthritis using the peptide library approach. Front Immunol. 2021;12:753400. doi:10.3389/fimmu.2021.753400; Colasanti T, Sabatinelli D, Mancone C, Giorgi A, Pecani A, Spinelli FR, et al. Homocysteinylated alpha 1 antitrypsin as an antigenic target of autoantibodies in seronegative rheumatoid arthritis patients. J Autoimmun. 2020;113:102470. doi:10.1016/j.jaut.2020.102470; Poulsen TBG, Damgaard D, Jørgensen MM, Senolt L, Blackburn JM, Nielsen CH, et al. Identification of potential autoantigens in anti-CCP-positive and anti-CCP-negative rheumatoid arthritis using citrulline-specific protein arrays. Sci Rep. 2021;11(1):17300. doi:10.1038/s41598-021-96675-z; Richter M, Krishnamurthy H, Posso S, Carlin J, Buckner J. Highthroughput testing for modified-protein antibodies in patients diagnosed with “seronegative” rheumatoid arthritis. Arthritis Rheumatol. 2021;73(Suppl 9). URL: https://acrabstracts.org/abstract/high-throughput-testing-for-modified-protein-antibodies-in-patients-diagnosed-with-seronegative-rheumatoid-arthritis/(Accessed: 29 April 2023).; Cunningham KY, Hur B, Gupta VK, Arment CA, Wright KA, Mason TG, et al. Patients with ACPA-positive and ACPA-negative rheumatoid arthritis show different serological autoantibody repertoires and autoantibody associations with disease activity. Sci Rep. 2023;13(1):5360. doi:10.1038/s41598-023-32428-4; Li K, Mo W, Wu L, Wu X, Luo C, Xiao X, et al. Novel autoantibodies identified in ACPA-negative rheumatoid arthritis. Ann Rheum Dis. 2021;80(6):739-747. doi:10.1136/annrheumdis-2020-218460; Gerlag DM, Raza K, van Baarsen LG, Brouwer E, Buckley CD, Burmester GR, et al. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann Rheum Dis. 2012;71(5):638-641. doi:10.1136/annrheumdis-2011-200990; Hensvold A, Klareskog L. Towards prevention of autoimmune diseases: The example of rheumatoid arthritis. Eur J Immunol. 2021;51(8):1921-1933. doi:10.1002/eji.202048952; Burgers LE, van Steenbergen HW, Ten Brinck RM, Huizinga TW, van der Helm-van Mil AH. Differences in the symptomatic phase preceding ACPA-positive and ACPA-negative RA: A longitudinal study in arthralgia during progression to clinical arthritis. Ann Rheum Dis. 2017;76(10):1751-1754. doi:10.1136/annrheumdis-2017-211325; van Boheemen L, Ter Wee MM, Falahee M, Filer A, van BeersTas M, Finckh A, et al. The Symptoms in Persons At Risk of Rheumatoid Arthritis (SPARRA) questionnaire: Predicting clinical arthritis development. Scand J Rheumatol. 2022 Sep 29:1-8. doi:10.1080/03009742.2022.2116806; Loza MJ, Nagpal S, Cole S, Laird RM, Alcala A, Rao NL, et al. Serologic biomarkers of progression toward diagnosis of rheumatoid arthritis in active component military personnel. Arthritis Rheumatol. 2022;74(11):1766-1775. doi:10.1002/art.42260; Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3-18. doi:10.1136/ard-2022-223356; Насонов ЕЛ, Каратеев ДЕ, Чичасова НВ. Новые рекомендации по лечению ревматоидного артрита (EULAR, 2013): место метотрексата. Научно-практическая ревматология. 2014;52(1):8-26. doi:10.14412/1995-4484-2014-8-26; Насонов ЕЛ. Метотрексат при ревматоидном артрите – 2015: новые факты и идеи. Научно-практическая ревматология. 2015;53(4):421-433. doi:10.14412/1995-4484-2015-421-433; Wevers-de Boer K, Visser K, Heimans L, Ronday HK, Molenaar E, Groenendael JH, et al. Remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis (the IMPROVED study). Ann Rheum Dis. 2012;71(9): 1472-1477. doi:10.1136/annrheumdis-2011-200736; Nordberg LB, Lillegraven S, Aga AB, Sexton J, Olsen IC, Lie E, et al. Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial. RMD Open. 2018;4(2):e000752. doi:10.1136/rmdopen-2018-000752; Duong SQ, Crowson CS, Athreya A, Atkinson EJ, Davis JM 3rd, Warrington KJ, et al. Clinical predictors of response to methotrexate in patients with rheumatoid arthritis: A machine learning approach using clinical trial data. Arthritis Res Ther. 2022;24(1):162. doi:10.1186/s13075-022-02851-5; Greenwood M, Shipa M, Yeoh SA, Roussou E, Mukerjee D, Ehrenstein MR. Methotrexate reduces withdrawal rates of TNF inhibitors due to ineffectiveness in rheumatoid arthritis but only in patients who are seropositive. Ann Rheum Dis. 2020;79(11):1516-1517. doi:10.1136/annrheumdis-2020-217725; Hernández-Breijo B, Brenis CM, Plasencia-Rodríguez C, Martínez-Feito A, Novella-Navarro M, Pascual-Salcedo D, et al. Methotrexate reduces the probability of discontinuation of TNF inhibitors in seropositive patients with rheumatoid arthritis. A real-world data analysis. Front Med (Lausanne). 2021;8:692557. doi:10.3389/fmed.2021.692557; Wientjes MHM, den Broeder AA, Welsing PMJ, Verhoef LM, van den Bemt BJF. Prediction of response to anti-TNF treatment using laboratory biomarkers in patients with rheumatoid arthritis: A systematic review. RMD Open. 2022;8(2):e002570. doi:10.1136/rmdopen-2022-002570; Takeuchi T, Miyasaka N, Inui T, Yano T, Yoshinari T, Abe T, et al. High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: A post hoc analysis of the RISING study. Arthritis Res Ther. 2017;19(1):194. doi:10.1186/s13075-017-1401-2; Hambardzumyan K, Hermanrud C, Marits P, Vivar N, Ernestam S, Wallman JK, et al.; SWEFOT study group. Association of female sex and positive rheumatoid factor with low serum infliximab and anti-drug antibodies, related to treatment failure in early rheumatoid arthritis: Results from the SWEFOT trial population. Scand J Rheumatol. 2019;48(5):362-366. doi:10.1080/03009742.2019.1602670; Shipa MRA, Di Cicco M, Balogh E, Nitu NA, Mainuddin MD, Bhadauria N, et al. Drug-survival profiling of second-line biologic therapy in rheumatoid arthritis: Choice of another TNFi or a biologic of different mode of action? Mod Rheumatol. 2022 Aug 3:roac086. doi:10.1093/mr/roac086; Isaacs JD, Cohen SB, Emery P, Tak PP, Wang J, Lei G, et al. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: A meta-analysis. Ann Rheum Dis. 2013;72(3):329-36. doi:10.1136/annrheumdis-2011-201117; Norris-Grey C, Cambridge G, Moore S, Reddy V, Leandro M. Long-term persistence of rituximab in patients with rheumatoid arthritis: An evaluation of the UCL cohort from 1998 to 2020. Rheumatology (Oxford). 2022;61(2):591-596. doi:10.1093/rheumatology/keab248; Sokolove J, Schiff M, Fleischmann R, Weinblatt ME, Connolly SE, Johnsen A, et al. Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. Ann Rheum Dis. 2016;75(4):709-714. doi:10.1136/annrheumdis-2015-207942; Alten R, Mariette X, Flipo RM, Caporali R, Buch MH, Patel Y, et al. Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: Real-world results from the ASCORE study: an international 2-year observational study. Clin Rheumatol. 2022;41(8):2361-2373. doi:10.1007/s10067-022-06176-1; Harrold LR, Connolly SE, Wittstock K, Zhuo J, Kelly S, Lehman T, et al. Baseline anti-citrullinated protein antibody status and response to abatacept or non-TNFi biologic/targeted-synthetic DMARDs: US observational study of patients with RA. Rheumatol Ther. 2022;9(2):465-480. doi:10.1007/s40744-021-00401-0; Bird P, Hall S, Nash P, Connell CA, Kwok K, Witcombe D, et al. Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in phase III randomised clinical trials of tofacitinib. RMD Open. 2019;5(1):e000742. doi:10.1136/rmdopen-2018-000742; Sugawara M, Fujieda Y, Noguchi A, Tanimura S, Shimizu Y, Nakagawa I, et al. Prediction of the intolerance or non-responder to Janus kinase inhibitors in patients with rheumatoid arthritis: A preliminary retrospective study with integrative cluster analysis. Clin Exp Rheumatol. 2022;40(9):1674-1680. doi:10.55563/clinexprheumatol/czhc93; Jung JY, Lee E, Kim JW, Suh CH, Kim HA. Efficacy and drug retention of tofacitinib in rheumatoid arthritis: From the nationwide Korean College of Rheumatology Biologics registry. Clin Exp Rheumatol. 2022 Aug 31. doi:10.55563/clinexprheumatol/6fcyza; Taylor PC, Alten R, Álvaro Gracia JM, Kaneko Y, Walls C, Quebe A, et al. Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy. RMD Open. 2022;8(1): e001994. doi:10.1136/rmdopen-2021-001994; Насонов ЕЛ, Лила АМ. Барицитиниб: новые возможности фармакотерапии ревматоидного артрита и других иммуновоспалительных ревматических заболеваний. Научно-практическая ревматология. 2020;58(3):304-316. doi:10.14412/1995-4484-2020-304-316; Каратеев АЕ. Проблемы боли и качества жизни при ревматоидном артрите: фокус на барицитиниб. Научно-практическая ревматология. 2020;58(4):420-427. doi:10.47360/1995-4484-2020-420-427; Dougados M, Taylor PC, Bingham CO 3rd, Fallon L, Brault Y, Roychoudhury S, et al. The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis. RMD Open. 2022;8(2):e002478. doi:10.1136/rmdopen-2022-002478; Willemze A, Trouw LA, Toes RE, Huizinga TW. The influence of ACPA status and characteristics on the course of RA. Nat Rev Rheumatol. 2012;8(3):144-152. doi:10.1038/nrrheum.2011.204; D’Onofrio B, van der Helm-van Mil A, Huizinga WJT, van Mulligen E. Inducibility or predestination? Queries and concepts around drug-free remission in rheumatoid arthritis. Expert Rev Clin Immunol. 2023;19(2):217-225. doi:10.1080/1744666X.2023.2157814; Amaya-Amaya J, Calixto OJ, Saade-Lemus S, Calvo-Paramo E, Mantilla RD, Rojas-Villarraga A, et al. Does non-erosive rheumatoid arthritis exist? A cross-sectional analysis and a systematic literature review. Semin Arthritis Rheum. 2015;44(5):489-498. doi:10.1016/j.semarthrit.2014.09.006; Andersson ML, Svensson B, Forslind K. Distribution of erosions in hands and feet at the time for the diagnosis of RA and during 8-year follow-up. Clin Rheumatol. 2021;40(5):1799-1810. doi:10.1007/s10067-020-0465-x; Bugatti S, Bogliolo L, Manzo A, De Stefano L, Delvino P, Motta F, et al. Impact of anti-citrullinated protein antibodies on progressive systemic bone mineral density loss in patients with early rheumatoid arthritis after two years of treat-to-target. Front Immunol. 2021;12:701922. doi:10.3389/fimmu.2021.701922; Svensson B, Andersson MLE, Gjertsson I, Hafström I, Ajeganova S, Forslind K. Erosion-free rheumatoid arthritis: clinical and conceptional implications – A BARFOT study. BMC Rheumatol. 2022;6(1):88. doi:10.1186/s41927-022-00317-4; Boeters DM, Burgers LE, Sasso EH, Huizinga TWJ, van der Helm-van Mil AHM. ACPA-negative RA consists of subgroups: patients with high likelihood of achieving sustained DMARD-free remission can be identified by serological markers at disease presentation. Arthritis Res Ther. 2019;21(1):121. doi:10.1186/s13075-019-1902-2; Verstappen M, Niemantsverdriet E, Matthijssen XME, le Cessie S, van der Helm-van Mil AHM. Early DAS response after DMARD-start increases probability of achieving sustained DMARD-free remission in rheumatoid arthritis. Arthritis Res Ther. 2020;22(1):276. doi:10.1186/s13075-020-02368-9; Verstappen M, van Steenbergen HW, de Jong PHP, van der Helm-van Mil AHM. Unraveling heterogeneity within ACPA-negative rheumatoid arthritis: The subgroup of patients with a strong clinical and serological response to initiation of DMARD treatment favor disease resolution. Arthritis Res Ther. 2022;24(1):4. doi:10.1186/s13075-021-02671-z; Cagnotto G, Jacobsson LTH, Rydell E, Eberhard A, Compagno M, Turesson C. Male sex predicts a favorable outcome in early ACPAnegative rheumatoid arthritis: Data from an observational study. J Rheumatol. 2022;49(9):990-997. doi:10.3899/jrheum.211199; Schäfer M, Albrecht K, Kekow J, Rockwitz K, Liebhaber A, Zink A, et al. Factors associated with treatment satisfaction in patients with rheumatoid arthritis: Data from the biological register RABBIT. RMD Open. 2020;6(3):e001290. doi:10.1136/rmdopen-2020-001290; Bugatti S, De Stefano L, Manzo A, Sakellariou G, Xoxi B, Montecucco C. Limiting factors to Boolean remission differ between autoantibody-positive and -negative patients in early rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2021;13:1759720X211011826. doi:10.1177/1759720X211011826; Ten Klooster PM, de Graaf N, Vonkeman HE. Association between pain phenotype and disease activity in rheumatoid arthritis patients: A non-interventional, longitudinal cohort study. Arthritis Res Ther. 2019;21(1):257. doi:10.1186/s13075-019-2042-4; Duffield SJ, Miller N, Zhao S, Goodson NJ. Concomitant fibromyalgia complicating chronic inflammatory arthritis: A systematic review and meta-analysis. Rheumatology (Oxford). 2018;57(8):1453-1460. doi:10.1093/rheumatology/key112; Pedersen M, Jacobsen S, Klarlund M, Pedersen BV, Wiik A, Wohlfahrt J, et al. Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides. Arthritis Res Ther. 2006;8(4):R133. doi:10.1186/ar2022; Lahiri M, Luben RN, Morgan C, Bunn DK, Marshall T, Lunt M, et al. Using lifestyle factors to identify individuals at higher risk of inflammatory polyarthritis (results from the European Prospective Investigation of Cancer-Norfolk and the Norfolk Arthritis Register – the EPIC-2-NOAR Study). Ann Rheum Dis. 2014;73(1): 219-226. doi:10.1136/annrheumdis-2012-202481; Wesley A, Bengtsson C, Elkan AC, Klareskog L, Alfredsson L, Wedrén S; Epidemiological Investigation of Rheumatoid Arthritis Study Group. Association between body mass index and anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis: Results from a population-based case-control study. Arthritis Care Res (Hoboken). 2013;65(1):107-112. doi:10.1002/acr.21749; Feng J, Chen Q, Yu F, Wang Z, Chen S, Jin Z, et al. Body mass index and risk of rheumatoid arthritis: A meta-analysis of observational studies. Medicine (Baltimore). 2016;95(8):e2859. doi:10.1097/MD.0000000000002859; Juan S, Jiabi Z. Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: A systematic review and meta-analysis. Joint Bone Spine. 2019;86(2):173-183. doi:10.1016/j.jbspin.2018.03.007; Ogdie A, Liu M, Rebello S, Cronin A, Dube B, McLean R, et al. Characteristics of patients with seropositive or seronegative rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis: Data from the US-based corrona rheumatoid arthritis and psoriatic arthritis/spondyloarthritis (PsA/SpA) registries. Arthritis Rheumatol. 2019;71(Suppl 10). URL: https://acrabstracts.org/abstract/characteristics-of-patients-with-seropositive-or-seronegative-rheumatoid-arthritis-psoriatic-arthritis-or-axial-spondyloarthritis-data-from-the-us-based-corrona-rheumatoid-arthritisand-psoriatic-a/ (Accessed: 22 April 2023).; Coskun Benlidayi I. Fibromyalgia interferes with disease activity and biological therapy response in inflammatory rheumatic diseases. Rheumatol Int. 2020;40(6):849-858. doi:10.1007/s00296-019-04506-2; Lwin MN, Serhal L, Holroyd C, Edwards CJ. Rheumatoid arthritis: The impact of mental health on disease: A narrative review. Rheumatol Ther. 2020;7(3):457-471. doi:10.1007/s40744-020-00217-4; Bugatti S, De Stefano L, D’Onofrio B, Nicrosini A, Mauric E, di Lernia M, et al. Inflammatory correlates of the patient global assessment of disease activity vary in relation to disease duration and autoantibody status in patients with rheumatoid arthritis. Ann Rheum Dis. 2022;81(9):1206-1213. doi:10.1136/annrheumdis-2022-222436; Насонов ЕЛ, Олюнин ЮА, Лила АМ. Ревматоидный артрит: проблемы ремиссии и резистентности к терапии. Научно-практическая ревматология. 2018;56(3):263-271. doi:10.14412/1995-4484-2018-263-271; Tan Y, Buch MH. ‘Difficult to treat’ rheumatoid arthritis: current position and considerations for next steps. RMD Open. 2022;8(2):e002387. doi:10.1136/rmdopen-2022-002387; Buch MH, Eyre S, McGonagle D. Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis. Nat Rev Rheumatol. 2021;17(1):17-33. doi:10.1038/s41584-020-00541-7; Merola JF, Espinoza LR, Fleischmann R. Distinguishing rheumatoid arthritis from psoriatic arthritis. RMD Open. 2018;4(2):e000656. doi:10.1136/rmdopen-2018-000656; Osman N, Mohamed FI, Hassan AA. Kamel SR, Ahmed SS. Frequency of inflammatory back pain and sacroiliitis in Egyptian patients with rheumatoid arthritis. Egypt J Radiol Nucl Med. 2019;50:25. doi:10.1186/s43055-019-0019-6; Nikiphorou E, Sjöwall C, Hannonen P, Rannio T, Sokka T. Long-term outcomes of destructive seronegative (rheumatoid) arthritis – Description of four clinical cases. BMC Musculoskelet Disord. 2016;17:246. doi:10.1186/s12891-016-1067-y; Kelkka T, Savola P, Bhattacharya D, Huuhtanen J, Lönnberg T, Kankainen M, et al. Adult-onset anti-citrullinated peptide antibody-negative destructive rheumatoid arthritis is characterized by a disease-specific CD8+ T lymphocyte signature. Front Immunol. 2020;11:578848. doi:10.3389/fimmu.2020.578848; Moon JS, Younis S, Ramadoss NS, Iyer R, Sheth K, Sharpe O, et al. Cytotoxic CD8+ T cells target citrullinated antigens in rheumatoid arthritis. Nat Commun. 2023;14(1):319. doi:10.1038/s41467-022-35264-8; McGonagle D, Aydin SZ, Gül A, Mahr A, Direskeneli H. ‘MHC-I-opathy’-unified concept for spondyloarthritis and Behçet disease. Nat Rev Rheumatol. 2015;11(12):731-740. doi:10.1038/nrrheum.2015.147; Насонов ЕЛ, Авдеева АС, Коротаева ТВ, Дубинина ТВ, Усачева ЮВ. Роль интерлейкина 17 в патогенезе ревматоидного артрита. Есть ли перспективы применения ингибиторов ИЛ-17? Научно-практическая ревматология. 2023;61(2):165-180. doi:10.47360/1995-4484-2023-165-180; Насонов ЕЛ, Лила АМ. Ингибиторы Янус-киназ при иммуновоспалительных ревматических заболеваниях: новые возможности и перспективы. Научно-практическая ревматология. 2019;57(1):8-16. doi:10.14412/1995-4484-2019-8-16; Petsch C, Araujo EG, Englbrecht M, Bayat S, Cavallaro A, Hueber AJ, et al. Prevalence of monosodium urate deposits in a population of rheumatoid arthritis patients with hyperuricemia. Semin Arthritis Rheum. 2016;45(6):663-668. doi:10.1016/j.semarthrit.2015.11.014; Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Goutassociated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237-241. doi:10.1038/nature04516; Mitrovic S, Fautrel B. Clinical phenotypes of adult-onset Still’s disease: New insights from pathophysiology and literature findings. J Clin Med. 2021;10(12):2633. doi:10.3390/jcm10122633; Насонов ЕЛ, Файст Е. Болезнь Стилла взрослых: новые горизонты. Научно-практическая ревматология. 2021;59(6):645-665. doi:10.47360/1995-4484-2021-643-663; Cutolo M, Cimmino MA, Sulli A. Polymyalgia rheumatica vs late-onset rheumatoid arthritis. Rheumatology (Oxford). 2009;48(2):93-95. doi:10.1093/rheumatology/ken294; Caporali R, Montecucco C, Epis O, Bobbio-Pallavicini F, Maio T, Cimmino MA. Presenting features of polymyalgia rheumatica (PMR) and rheumatoid arthritis with PMR-like onset: A prospective study. Ann Rheum Dis. 2001;60(11):1021-1024. doi:10.1136/ard.60.11.1021; Floris A, Piga M, Cauli A, Salvarani C, Mathieu A. Polymyalgia rheumatica: An autoinflammatory disorder? RMD Open. 2018;4(1):e000694. doi:10.1136/rmdopen-2018-000694; Inanir A, Yigit S, Karakus N, Tekin S, Rustemoglu A. Association of MEFV gene mutations with rheumatoid factor levels in patients with rheumatoid arthritis. J Investig Med. 2013;61(3):593-596. doi:10.2310/JIM.0b013e318280a96e; Koca SS, Etem EO, Isik B, Yuce H, Ozgen M, Dag MS, Isik A. Prevalence and significance of MEFV gene mutations in a cohort of patients with rheumatoid arthritis. Joint Bone Spine. 2010;77(1):32-35. doi:10.1016/j.jbspin.2009.08.006; Cañete JD, Arostegui JI, Queiró R, Gratacós J, Hernández MV, Larrosa M, et al. An unexpectedly high frequency of MEFV mutations in patients with anti-citrullinated protein antibodynegative palindromic rheumatism. Arthritis Rheum. 2007;56(8):2784-2788. doi:10.1002/art.22755; Cuervo A, Sanmartí R, Ramírez J, Castellanos-Moreira R, Inciarte-Mundo J, Aróstegui JI, et al. Palindromic rheumatism: Evidence of four subtypes of palindromic-like arthritis based in either MEFV or rheumatoid factor/ACPA status. Joint Bone Spine. 2021;88(6):105235. doi:10.1016/j.jbspin.2021.105235; Tani Y, Kishi T, Miyamae T, Kawamoto M, Kawaguchi Y, Taniguchi A, et al. The evaluation of gene polymorphisms associated with autoinflammatory syndrome in patients with palindromic rheumatism complicated by intermittent hydrarthrosis. Clin Rheumatol. 2020;39(3):841-845. doi:10.1007/s10067-019-04883-w; Zhong L, Song H, Wang W, Li J, Ma M. MEFV M694V mutation has a role in susceptibility to ankylosing spondylitis: A meta-analysis. PLoS One. 2017;12(8):e0182967. doi:10.1371/journal.pone.0182967; Özen S, Batu ED, Demir S. Familial Mediterranean fever: Recent developments in pathogenesis and new recommendations for management. Front Immunol. 2017;8:253. doi:10.3389/fimmu.2017.00253; Алекберова ЗС, Насонов ЕЛ. Перспективы применения колхицина в медицине: новые данные. Научно-практическая ревматология. 2020;58(2):183-190. doi:10.14412/1995-4484-2020-183-190; Насонов ЕЛ, Самсонов МЮ. Роль интерлейкина 1 в развитии заболеваний человека: фокус на анакинре (рецепторном антагонисте ИЛ-1). Научно-практическая ревматология. 2022; 60(3):280-298. doi:10.47360/1995-4484-2022-280-298; Насонов ЕЛ. Ингибиция иммунных контрольных точек и аутоиммунитет: ревматологические проблемы. Научно-практическая ревматология. 2018;56(1):5-9. doi:10.14412/1995-4484-2018-5-9; Dang QM, Watanabe R, Shiomi M, Fukumoto K, Nobashi TW, Okano T, et al. Rheumatic immune-related adverse events due to immune checkpoint inhibitors – A 2023 update. Int J Mol Sci. 2023;24(6):5643. doi:10.3390/ijms24065643; Albayda J, Dein E, Shah AA, Bingham CO 3rd, Cappelli L. Sonographic findings in inflammatory arthritis secondary to immune checkpoint inhibition: A case series. ACR Open Rheumatol. 2019;1(5):303-307. doi:10.1002/acr2.1026; Bronstein Y, Ng CS, Hwu P, Hwu WJ. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR Am J Roentgenol. 2011;197(6):W992-W1000. doi:10.2214/AJR.10.6198; Feist J, Murray A, Skapenko A, Schulze-Koops H. A Rare side effect of checkpoint inhibitor therapy-nivolumab-induced axial polyarthritis of the facet and costovertebral joints. Arthritis Rheumatol. 2019;71(11):1823. doi:10.1002/art.41036; Cappelli LC, Darrah E, Shah AA, Bingham CO. Patients with checkpoint inhibitor-induced inflammatory arthritis do not become seropositive for anti-cyclic citrullinated peptide when followed over time. ACR Open Rheumatol. 2022;4(1):83-84. doi:10.1002/acr2.11363; Ghosh N, Tiongson MD, Stewart C, Chan KK, Jivanelli B, Cappelli L, et al. Checkpoint inhibitor-associated arthritis: A systematic review of case reports and case series. J Clin Rheumatol. 2021;27(8):e317-e322. doi:10.1097/RHU.0000000000001370; Cappelli LC, Bingham CO, Forde PM, Anagnostou V, Brahmer J, Lipson EJ, et al. Anti-RA33 antibodies are present in a subset of patients with immune checkpoint inhibitor-induced inflammatory arthritis. RMD Open. 2022;8(2):e002511. doi:10.1136/rmdopen-2022-002511; Насонов ЕЛ. Абатацепт при ревматоидном артрите: новая форма, новые механизмы, новые возможности. Научно-практическая ревматология. 2015;53(5):522-541. doi:10.14412/1995-4484-2015-522-541; Farisogullari B, Pinto AS, Machado PM. COVID-19-associated arthritis: An emerging new entity? RMD Open. 2022;8(2): e002026. doi:10.1136/rmdopen-2021-002026; Wang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR, et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021;595(7866):283-288. doi:10.1038/s41586-021-03631-y; Damoiseaux J, Dotan A, Fritzler MJ, Bogdanos DP, Meroni PL, Roggenbuck D, et al. Autoantibodies and SARS-CoV2 infection: The spectrum from association to clinical implication: Report of the 15th Dresden Symposium on Autoantibodies. Autoimmun Rev. 2022;21(3):103012. doi:10.1016/j.autrev.2021.103012; Lacagnina MJ, Heijnen CJ, Watkins LR, Grace PM. Autoimmune regulation of chronic pain. Pain Rep. 2021;6(1): e905. doi:10.1097/PR9.0000000000000905; Goebel A, Andersson D, Helyes Z, Clark JD, Dulake D, Svensson C. The autoimmune aetiology of unexplained chronic pain. Autoimmun Rev. 2022;21(3):103015. doi:10.1016/j.autrev.2021.103015; Tsigalou C, Vallianou N, Dalamaga M. Autoantibody production in obesity: Is there evidence for a link between obesity and autoimmunity? Curr Obes Rep. 2020;9(3):245-254. doi:10.1007/s13679-020-00397-8; de Jonge H, Iamele L, Maggi M, Pessino G, Scotti C. Anti-cancer auto-antibodies: Roles, applications and open issues. Cancers (Basel). 2021;13(4):813. doi:10.3390/cancers13040813; Wang Y, Lloyd KA, Melas I, Zhou D, Thyagarajan R, Lindqvist J, et al. Rheumatoid arthritis patients display B-cell dysregulation already in the naïve repertoire consistent with defects in B-cell tolerance. Sci Rep. 2019;9(1):19995. doi:10.1038/s41598-019-56279-0; Mahendra A, Yang X, Abnouf S, Adolacion JRT, Park D, Soomro S, et al. Beyond autoantibodies: Biologic roles of human autoreactive B cells in rheumatoid arthritis revealed by RNA-sequencing. Arthritis Rheumatol. 2019;71(4):529-541. doi:10.1002/art.40772; Rönnelid J, Turesson C, Kastbom A. Autoantibodies in rheumatoid arthritis – Laboratory and clinical perspectives. Front Immunol. 2021;12:685312. doi:10.3389/fimmu.2021.685312; Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019;71(9):1400-1412. doi:10.1002/art.40930
-
5Academic Journal
Συγγραφείς: Vladimir Ivanovich Vasilyev, V R Gorodetsky, O A Logvinenko, S Kh Sedyshev, E N Aleksandrova, S G Palshina, S G Radenska-Lopovok, S S Nikitin, S K Solovyev, E L Nasonov, E Yu Varlamova, N A Probatova, A I Pavlovskaya, M A Frenkel, В. И. Васильев, В. Р. Городецкий, О. А. Логвиненко, С. Х. Седышев, Елена Николаевна Александрова, С. Г. Пальшина, С. С. Никитин, Сергей Константинович Соловьев, Евгений Львович Насонов, Е. Ю. Варламова, Н. А. Пробатова, А. И. Павловская, М. А. Френкель
Πηγή: Rheumatology Science and Practice; Vol 50, No 2 (2012); 35-43 ; Научно-практическая ревматология; Vol 50, No 2 (2012); 35-43 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2012-2
Θεματικοί όροι: monoclonal immunoglobulins and their к/λ light chains, multiple myeloma, solitary plasmacytoma, Bence-Jones myeloma, immunoglobulin light-chain amyloidosis, Waldenstrom’s macroglobulinemia, seronegative rheumatoid arthritis, systemic lupus erythematosus, множественная миелома, солитарная плазмоцитома, миелома Бенс-Джонса, амилоидоз легких цепей иммуноглобулинов, макроглобулинемия Вальденстрема, серонегативный ревматоидный артрит, системная красная волчанка, моноклональные иммуноглобулины и их легкие к/λ-цепи
Περιγραφή αρχείου: application/pdf
Relation: https://rsp.mediar-press.net/rsp/article/view/1165/837; Kyle R. The monoclonal gammapathies. Clin Chem 1994;40:2154-61. Андреева Н.Е., Чернохвостова Е.В. Иммуноглобулинопатии. М.: Медицина, 1985;240 с. Goeken J., Keren D. Introduction the report of the consensus conference on monoclonal gammopathies. Arch Pathol Lab Med 1999;123:104-5. Варламова Е.Ю. Иммунохимическая диагностика парапротеинемий. Клиническая онкогематология. Под ред М.А. Волкова. М.: Медицина, 2001;411-9. Логвиненко О.А., Васильев В.И. Моноклональная секреция и болезнь Шёгрена. Тер арх 2006;12:85-91. Логвиненко О.А., Васильев В.И. Ассоциации между болезнью Шёгрена и лимфомами. Науч-практич ревматол 2006;3:67-76. Васильев В.И., Пробатова Н.А., Тупицин Н.Н. и др. Лимфопролиферативные заболевания при болезни Шёгрена. Онкогематология 2007;3:16-27. Васильев В.И., Пробатова Н.А., Варламова Е.Ю. и др. Прогностическое значение смешанной моноклональной криоглобулинемии при болезни Шёгрена. Тер арх 2004;8:61-8. Васильев В.И., Пробатова Н.А., Тупицин Н.Н. и др. MALT-лимфомы при болезни Шёгрена. Тер арх 2006;1:45-52. Васильев В.И., Городецкий В.Р., Логвиненко О.А. и др. Дифференциальная диагностика плазматических дискразий в ревматологической практике. Совр ревматол 2010;4:16-24. Osterland C. Monoclonal gammopathies - their identification and biological significance. Clin Chim Acta 1989;180:1-22. Kyle R., Rajkumar S. Monoclonal gammopathies of undetermined significance. Best Pract Res Clin Haematol 2005;18:689-707. Городецкий В.Р., Пробатова Н.А., Васильев В.И. и др. Первичная плазмоцитома лимфатических узлов. Гематол трансфузиол 2006;51(5):3-8. Васильев В.И., Городецкий В.Р., Седышев С.Х. и др. Клинические проявления васкулита в дебюте множественной миеломы. Науч-практич ревматол 2010;1:81-7. Brouet J.-C., Clauvel J.-P., Danon F. еt al. Biologic and clinical significance of cryoglobulins. Review. A report of 86 cases. Amer J Med 1974;57:775-87. Naschitz J.E. Rheumatic syndromes: dues to occult neoplasia. Curr Opin Rheumatol 2001;13:62-6. Blade J., Kyle R.A. Monoclonal gammopathies of undertermined significance. Myeloma. Biology and management. Eds J.S. Malpas, D.E. Bersagel, R.A. Kyle, K.S. Anderson. Oxford: Oxford medical publications, 1998;514—41. Rajkumar S.V., Kyle R.A. (eds). Treatment of multiple myeloma and related disorders. New York: Cambridge University Press, 2009;1-195. Smedby K.E., Baecklund E., Askling J. Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Review. Cancer Epidem Biomarkers Prev 2006;15(11):2069—77. Zintzaras E., Voulgarelis M., Moutsopoulos H.M. The risk of lymphoma development in autoimmune diseases. A meta-analysis. Arch Intern Med 2005;165(14):2337-44. Askling J., Bongartz T. Malignancy and biologic therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008;20:334-9. Kiltz U., Brandt J., Zochling J., Braun J. Rheumatic manifestations of lymphoproliferative disorders. Clin Exp Rheumat 2007;25:35-9. Vital E.M., Emery P. Rheumatological manifestations of malignant haematological conditions. Reports on the rheumatic diseases series 5. Topical Reviews 2007;11:1-8. Manganelli P., Fietta P., Quaini F. Hematologic manifestations of primary Sjogren’s syndrome. Clin Exp Rheumatol 2006;24:438-48. Leandro M.J., Isenberg D.A. Rheumatic diseases and malignancy -is there an association? Scand J Rheumatol 2001;30:185-8. Saadoun D., Sellam J., Ghillani-Dalbin P. et al. Increased risks of lymphoma and death among patients with non-hepatitis C virus -related mixed cryoglobulinemia. Arch Intern Med 2006;166(23):2101-8. Kurzrock R., Cohen P.R. Vasculitis and cancer. Clin Dermatol 1993;11(1):175-87. Васильев В.И., Седышев С.Х., Городецкий В.Р. и др. Сухой синдром как проявление AL-амилоидоза. Науч-практич ревматол 2011;5:92-7. Андреева Н.Е., Балакирева Т.В. Множественная миелома. В кн.: Руководство по гематологии. Том 2. Под ред. А.И. Воробьева. М.: Ньюдиамед, 2003;151 —73. Насонов Е.Л., Насонова В.А. (ред.). Национальное руководство по ревматологии. М.: ГЭОТАР-Медиа, 2008. Gertz M.A., Comenzo R., Falk R.H. et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th. International Symposium on Amyloid and Amyloidosis. Amer J Hemat 2005;79:319-28. Городецкий В.Р., Пробатова Н.А., Логвиненко О.А. и др. Трудности диагностики лимфоидных неоплазий у больных ревматоидным артритом. Науч-практич ревматол 2009;3:94-100. Логвиненко О.А., Васильев В.И. Неходжкинские лимфомы при ревматических заболеваниях. Науч-практич ревматол 2011;5:71-82. Пальшина С.Г., Васильев В.И. Криоглобулинемический васкулит. Науч-практич ревматол 2010;4:59-66. Schima W., Amman G., Steiner E. et al. Case report: Sicca syndrome due to primary amyloidosis. Br J Radiol 1994;67:1023-5. Jardinet D., Westhovens R., Peeters J. Sicca syndrome as an initional symptom of amyloidosis. Clin Rheumatol 1998;17:546-8. Kojima M., Itoh H., Shimizu K. et al. Malignant lymphoma in patients with systemic rheumatic disease (rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, and dermatomyositis): a clinicopathologic study of 24 Japanese cases. Int Surg Pathol 2006;14(1):43-8. Fujishima M., Komatsuda A., Imai H. et al. Amyloid arthropathy resembling seronegative rheumatoid arthritis in a patient with IgD-k multiple myeloma. Intern Med 2003;42:121-4. Prokaewa T., Spencer B., Kaut M. et al. Soft tissue, joint and bone manifestation of AL amyloidosis. Arthr Rheum 2007;56:3858-68.
-
6Academic Journal
Συγγραφείς: Васильев, Владимир, Городецкий, В., Логвиненко, О., Седышев, С., Александрова, Е., Пальшина, С., Раденска-лоповок, С., Никитин, С., Соловьев, С., Насонов, Е., Варламова, Е., Пробатова, Н., Павловская, А., Френкель, М.
Θεματικοί όροι: ПЛАЗМАТИЧЕСКИЕ ДИСКРАЗИИ, МНОЖЕСТВЕННАЯ МИЕЛОМА, СОЛИТАРНАЯ ПЛАЗМОЦИТОМА, МИЕЛОМА БЕНС-ДЖОНСА, АМИЛОИДОЗ ЛЕГКИХ ЦЕПЕЙ ИММУНОГЛОБУЛИНОВ, МАКРОГЛОБУЛИНЕМИЯ ВАЛЬДЕНСТРЕМА, СЕРОНЕГАТИВНЫЙ РЕВМАТОИДНЫЙ АРТРИТ, СИСТЕМНАЯ КРАСНАЯ ВОЛЧАНКА, МОНОКЛОНАЛЬНЫЕ ИММУНОГЛОБУЛИНЫ И ИХ ЛЕГКИЕ К/λ-ЦЕПИ, WALDENSTROM’S MACROGLOBULINEMIA, MONOCLONAL IMMUNOGLOBULINS AND THEIR К/λ LIGHT CHAINS
Περιγραφή αρχείου: text/html
-
7Academic Journal
Συγγραφείς: Лалаев, Э. Э.
Θεματικοί όροι: серонегативный ревматоидный артрит
Relation: Лалаев, Э. Э. Особенности клинического течения серонегативного ревматоидного артрита [Электронный ресурс] / Э. Э. Лалаев // Проблемы и перспективы развития современной медицины : сб. науч. ст. XII Респ. науч.-практ. конф. с междунар. участием студентов и молодых ученых, Гомель, 8 окт. 2020 г. : в 8 т. / Гомел. гос. мед. ун-т; редкол. : А. Н. Лызиков [и др.]. – Гомель : ГомГМУ, 2020. – Т. 2. – С. 103–105. – 1 электрон. опт. диск (CD-ROM). Научный руководитель: к.м.н., доцент Е. М. Хардикова; http://elib.gsmu.by/handle/GomSMU/7757
Διαθεσιμότητα: http://elib.gsmu.by/handle/GomSMU/7757
-
8Academic Journal
Συγγραφείς: Саварина, В. А.
Θεματικοί όροι: серонегативный ревматоидный артрит, эссенциальная тромбоцитемия, гидроксикарбамид, меркаптопурин, аспирин, метотрексат, seronegative rheumatoid arthritis, essential thrombocythemia, hydroxycarbamide, mercaptopurine, aspirin, methotrexate
Relation: Саварина, В. А. Ремиссия серонегативного ревматоидного артрита на фоне лечения эссенциальной тромбоцитемии меркаптопурином и гидроксикарбамидом / В. А. Саварина // Проблемы здоровья и экологии. – 2020. – № 1 (63). – С. 94–97.; http://elib.gsmu.by/handle/GomSMU/7095
Διαθεσιμότητα: http://elib.gsmu.by/handle/GomSMU/7095
-
9Academic Journal
Πηγή: Научно-практическая ревматология.
Θεματικοί όροι: 03 medical and health sciences, 0302 clinical medicine, ПЛАЗМАТИЧЕСКИЕ ДИСКРАЗИИ, МНОЖЕСТВЕННАЯ МИЕЛОМА, СОЛИТАРНАЯ ПЛАЗМОЦИТОМА, МИЕЛОМА БЕНС-ДЖОНСА, АМИЛОИДОЗ ЛЕГКИХ ЦЕПЕЙ ИММУНОГЛОБУЛИНОВ, МАКРОГЛОБУЛИНЕМИЯ ВАЛЬДЕНСТРЕМА, СЕРОНЕГАТИВНЫЙ РЕВМАТОИДНЫЙ АРТРИТ, СИСТЕМНАЯ КРАСНАЯ ВОЛЧАНКА, МОНОКЛОНАЛЬНЫЕ ИММУНОГЛОБУЛИНЫ И ИХ ЛЕГКИЕ К/λ-ЦЕПИ, WALDENSTROM'S MACROGLOBULINEMIA, MONOCLONAL IMMUNOGLOBULINS AND THEIR К/λ LIGHT CHAINS, 3. Good health
Περιγραφή αρχείου: text/html
